Brigitte Bosman

A phase II dose-ranging study of mirabegron in patients with overactive bladder

Christopher R. Chapple, Vladimír Dvořák, Philip Van Kerrebroeck et al. · International Urogynecology Journal · 2013 · 134 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical Trial

Donald Newgreen, Brigitte Bosman, Adriana Hollestein-Havelaar et al. · European Urology · 2016 · 42 citations

Medicine, Pediatrics, Pharmacology +13

Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder

Donald Newgreen, Brigitte Bosman, Adriana Hollestein-Havelaar et al. · The Journal of Urology · 2017 · 25 citations

Medicine, Pediatrics, Pharmacology +17

Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies

Israel Franco, Piet Hoebeke, Małgorzata Baka‐Ostrowska et al. · Journal of Pediatric Urology · 2019 · 23 citations · Full text

Medicine, Pediatrics, Pharmacology +15

The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model–based pediatric dose estimation

Søren Rittig, Małgorzata Baka‐Ostrowska, Camilla Tøndel et al. · Journal of Pediatric Urology · 2019 · 17 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17